That Virofree was able to decrease TNF-α secretion amount, fibrosis-related protein expression in vitro (Figure 6; Supplementary Figure S9), and improve physiological indexes of ARDS rats in the preliminary in vivo, and results suggest that Virofree is a potential anti-COVID-19 and anti-fibrosis treatment. This evidence concerns the gene TNF and COVID-19.